Drugs / Fludaribine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03314974 | Mar 2018 → Jun 2027 expected | Burkitt lymphoma, T-cell and NK-cell neoplasm, acute biphenotypic leukemia, anemia +15 | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fludaribine | “Day -5 to Day -2: Busulfan and Fludaribine” NCT03314974 ↗ |